ME 143

Drug Profile

ME 143

Alternative Names: ME-143; NV-143

Latest Information Update: 12 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novogen
  • Developer MEI Pharma
  • Class Antineoplastics; Isoflavones; Small molecules
  • Mechanism of Action NADH oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 13 Apr 2016 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 28 Jun 2012 Marshall Edwards is now called MEI Pharma
  • 01 Jun 2012 Marshall Edwards completes a phase I trial in Solid tumours (refractory disease) in USA (NCT01401868)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top